Vivasure treats first patients with percutaneous vessel closure device

Vivasure Medical announced today that the first patient received treatment with its PerQseal Elite large-hole closure system.

Galway, Ireland-based Vivasure designed the latest-generation PerQseal Elite for percutaneous vessel closure. It leverages the legacy platform’s safety profile and ease of use while allowing for faster delivery. The new system also improves performance in calcium and the treatment of large-hole venous procedures. That includes transcatheter mitral valve repair and replacement.

According to a news release, PerQseal is the first sutureless, fully absorbable synthetic implant for large-bore vessel punctures. Placement occurs from inside the vessel, making deployment simpler and more controlled than conventional closure techniques.

Large-hole access is required for percutaneous cardiovascular procedures, including transcatheter aortic valve repair (TAVR). Other relevant procedures include thoracic and abdominal endovascular aneu…

Read more
  • 0

Contract manufacturer selection tips, tricks and red flags

A few years ago, Vivasure Medical faced an emergency that “nearly shut our company down,” co-founder Gerard Brett said.

“We picked a supplier in good faith — it looked like they had what it took to do the job for us,” he said. “We were working away at developing a part of our product, and we got a phone call with 24 hours’ notice to say the sheriff is going to put a lock on the door of that company.”

The supplier was about 4,500 miles from Vivasure’s Galway, Ireland headquarters where Brett serves as chief operating officer.

“We literally put people on a plane, hired what looked like the CIA, we had black Suburbans, and we backed up to the back of that facility at 2 a.m. and took our stuff out: equipment and materials,” Brett said. “At 6 a.m., it was locked.”

Vivasure Medical co-founder and Chief Operating Officer Gerard B…

Read more
  • 0

Vivasure wins FDA IDE approval, receives €30M from Haemonetics

Vivasure Medical announced today that it received FDA investigational device exemption (IDE) to advance a clinical study of its PerQseal device.

Additionally, Galway, Ireland-based Vivasure announced a €30 million ($32.2 million) investment from Haemonetics. It marks part of the company’s Series D financing, for which the initial $23 million tranche closed in May 2022. The agreement includes an option for Haemonetics to acquire Vivasure.

Vivasure Medical develops a portfolio of fully absorbable, patch-based, large-bore percutaneous vessel closure devices. Uses for the devices include transcatheter endovascular and cardiovascular procedures.

About the Vivasure Patch pivotal study

Vivasure’s Patch clinical study evaluates the safety and effectiveness of the Vivasure PerQseal closure device system. The multi-center, single-arm, pivotal study will enroll up to 188 patients across the U.S. and Europe. Vivasure intends to use clinical results to su…

Read more
  • 0

Vivasure raises $23M initial Series D tranche; could reach up to $54M

Vivasure Medical announced today that it closed the first tranche — worth $23 million — of its Series D financing round.

Galway, Ireland-based Vivasure’s $23 million (€22 million) fundraising tranche could make up a chunk of the Series D that could reach up to $54 million (€52 million) in total.

According to a news release, an unnamed multi-national strategic corporation led the financing, which includes an option to buy the company upon certain milestones. Other participants included a second unnamed strategic corporate investor and existing investors Fountain Healthcare Partners, Orchestra BioMed, LSP Health Economics Fund managed by the EQT Life Sciences team, Panakès Partners and Evonik Venture Capital.

The funds will be used to support the U.S. and European clinical development and regulatory processes for the company’s portfolio of fully absorbable, patch-based, large-bore percutaneous vessel closure devices for transcatheter endovascul…

Read more
  • 0

Vivasure treats first patient in U.S. study for next-gen PerQseal+ in TAVR procedures

Vivasure Medical announced today that the first patient was treated in a U.S. early feasibility study of its next-generation PerQseal+ device.

Galway, Ireland-based Vivasure’s study will evaluate PerQseal+ in percutaneous transcatheter aortic valve replacement (TAVR) procedures. The first patient was treated by Dr. Robert Pyo at Stony Brook University Hospital in Stony Brook, New York.

The company designed PerQseal+ to provide physicians with an option for managing challenges and bleeding complications associated with large-bore arterial vessel closure, according to a news release.

Vivasure’s first-generation PerQseal device, a sutureless and fully absorbable synthetic implant for large-bore arterial vessel punctures, is available in Europe. That version has an intravascular patch that seals the vessel from the inside, while the PerQseal+ has an enhanced bioabsorbable patch designed to address more complex patient anatomies. The next-generati…

Read more
  • 0